Rossi Tomin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rossi Tomin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Christine Sexton
Centre for Multimodal Sensorimotor and Pain Research, Faculty of Dentistry, University of Toronto, Toronto, ON, Canada
3 shared publications - Massieh Moayedi
University of Toronto
3 shared publications - Stephanie L. Bourke
Centre for Multimodal Sensorimotor and Pain Research, Faculty of Dentistry, University of Toronto, Toronto, ON, Canada
3 shared publications C. Kyeremaa-Adjei
Pharmacology and Therapeutics, School of Pharmacy and Medical Sciences, Institute for Health Discovery and Innovation, Institute for Clinical Trials, University of Galway, Galway, Ireland
2 shared publications- David P. Finn
Pharmacology and Therapeutics, School of Medicine, University of Galway, Galway, Ireland
2 shared publications - Isabelle Boileau
Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Canada
2 shared publications
Latest Publications
- Open Access
The Endocannabinoid System’s Contribution to Placebo Analgesia
Placebo analgesia—pain reduction from inert treatments—varies widely across individuals, yet its neurochemical basis remains poorly understood. While endogenous opioids, specifically β-endorphin, contribute to placebo effects, mu-opioid receptor blockade does not fully abolish analgesia, implicating additional systems. Here, we investigate the endogenous cannabinoid (eCB) system’s contribution to placebo analgesia in 48 healthy adults using a validated placebo paradigm with blood sampling. We quantified circulating levels of eCB ligands and β-endorphin at baseline, as well as before and after placebo and control conditions to determine condition-related changes. Individual differences in placebo analgesia were associated with increases in fatty acid amide hydrolase (FAAH) substrates—a composite of anandamide, palmitoylethanolamide, and oleoylethanolamide—but not 2-arachidonoylglycerol or β-endorphin alone. Critically, β-endorphin moderated this relationship: FAAH substrates were strongly associated with pain reduction only when β-endorphin levels were low. These findings provide evidence that eCB and opioid systems interact in a state-dependent manner during placebo analgesia in humans, with implications for understanding individual variability in treatment responses.
Open AccessThe Endocannabinoid System’s Contribution to Placebo Analgesia
Placebo analgesia—pain reduction from inert treatments—varies widely across individuals, yet its neurochemical basis remains poorly understood. While endogenous opioids, specifically β-endorphin, contribute to placebo effects, mu-opioid receptor blockade does not fully abolish analgesia, implicating additional systems. Here, we investigate the endogenous cannabinoid (eCB) system’s contribution to placebo analgesia in 48 healthy adults using a validated placebo paradigm with blood sampling. We quantified circulating levels of eCB ligands and β-endorphin at baseline, as well as before and after placebo and control conditions to determine condition-related changes. Individual differences in placebo analgesia were associated with increases in fatty acid amide hydrolase (FAAH) substrates—a composite of anandamide, palmitoylethanolamide, and oleoylethanolamide—but not 2-arachidonoylglycerol or β-endorphin alone. Critically, β-endorphin moderated this relationship: FAAH substrates were strongly associated with pain reduction only when β-endorphin levels were low. These findings provide evidence that eCB and opioid systems interact in a state-dependent manner during placebo analgesia in humans, with implications for understanding individual variability in treatment responses.
- 24 November 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (4) , 854-865
The contribution of baseline circulating endocannabinoids to individual differences in human pain sensitivity: a quantitative sensory testing study
The endocannabinoid (eCB) system comprises cannabinoid receptors; endogenous ligands, including anandamide (AEA), 2-arachidonoylglycerol (2-AG); and related N -acylethanolamines (NAEs), N- palmitoylethanolamide (PEA), and N- oleoylethanolamide (OEA); and metabolizing enzymes (eg, fatty acid amide hydrolase [FAAH]). The eCB system modulates nociceptive circuits in rodents. In humans, the FAAH C385A polymorphism is associated with reduced pain sensitivity, suggesting eCB tone contributes to individual pain differences, but this has yet to be tested. Here, we determined whether the eCB system is associated with somatosensory and pain sensitivity measured with quantitative sensory testing (QST) in 91 healthy participants (39 males, 52 females). We tested 3 hypotheses: (1) FAAH C385A polymorphism, cannabis use, and sex affect serum eCB/NAE concentrations; (2) FAAH C385A carriers show altered pain sensitivity vs noncarriers; and (3) baseline serum eCB/NAE concentrations are associated with QST measures. eCB/NAE concentrations were not statistically different based on sex ( P > 0.05), FAAH genotype ( P > 0.05), or cannabis use ( P > 0.05). To address collinearity of AEA, OEA, and PEA, we performed a principal components analysis, which identified a single component of FAAH substrates. Linear regressions found that FAAH genotype did not affect QST measures and that baseline 2-AG and FAAH substrate concentrations were not associated with QST measures, except pressure pain thresholds (PPT; P = 0.003), which were associated with AEA and OEA. Baseline eCB/NAE levels and FAAH genotype are not associated with the outcome measures of standard QST tests that rely on point estimates in healthy adult humans; nonetheless, circulating FAAH substrate levels were associated with PPT.
- 24 November 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (4) , 854-865
The contribution of baseline circulating endocannabinoids to individual differences in human pain sensitivity: a quantitative sensory testing study
The endocannabinoid (eCB) system comprises cannabinoid receptors; endogenous ligands, including anandamide (AEA), 2-arachidonoylglycerol (2-AG); and related N -acylethanolamines (NAEs), N- palmitoylethanolamide (PEA), and N- oleoylethanolamide (OEA); and metabolizing enzymes (eg, fatty acid amide hydrolase [FAAH]). The eCB system modulates nociceptive circuits in rodents. In humans, the FAAH C385A polymorphism is associated with reduced pain sensitivity, suggesting eCB tone contributes to individual pain differences, but this has yet to be tested. Here, we determined whether the eCB system is associated with somatosensory and pain sensitivity measured with quantitative sensory testing (QST) in 91 healthy participants (39 males, 52 females). We tested 3 hypotheses: (1) FAAH C385A polymorphism, cannabis use, and sex affect serum eCB/NAE concentrations; (2) FAAH C385A carriers show altered pain sensitivity vs noncarriers; and (3) baseline serum eCB/NAE concentrations are associated with QST measures. eCB/NAE concentrations were not statistically different based on sex ( P > 0.05), FAAH genotype ( P > 0.05), or cannabis use ( P > 0.05). To address collinearity of AEA, OEA, and PEA, we performed a principal components analysis, which identified a single component of FAAH substrates. Linear regressions found that FAAH genotype did not affect QST measures and that baseline 2-AG and FAAH substrate concentrations were not associated with QST measures, except pressure pain thresholds (PPT; P = 0.003), which were associated with AEA and OEA. Baseline eCB/NAE levels and FAAH genotype are not associated with the outcome measures of standard QST tests that rely on point estimates in healthy adult humans; nonetheless, circulating FAAH substrate levels were associated with PPT.
- Open Access
The Contribution of Baseline Circulating Endocannabinoids to Individual Differences in Human Pain Sensitivity: A Quantitative Sensory Testing Study
The endocannabinoid (eCB) system—comprising cannabinoid receptors, eCBs (anandamide— AEA, 2-arachidonoylglycerol—2-AG) and related N -acylethanolamines (NAEs; N- palmitoylethanolamide—PEA, and N- oleoylethanolamide—OEA), and metabolizing enzymes (e.g., fatty acid amide hydrolase; FAAH)—modulates nociceptive circuits in rodents. In humans, the FAAH C385A polymorphism is associated with reduced pain sensitivity, suggesting eCB tone influences individual pain differences, but this has yet to be tested. Here, we determined whether the eCB system is associated with somatosensory and pain sensitivity measured with quantitative sensory testing (QST) in 91 healthy participants (39 males, 52 females). We tested three hypotheses: (1) FAAH C385A polymorphism, cannabis use, and sex affect serum eCB/NAE concentrations; (2) FAAH C385A carriers show altered pain sensitivity versus non-carriers; and (3) baseline serum eCB/NAE concentrations are associated with QST measures. eCB/NAE concentrations were not statistically different based on sex ( p > .05), based on FAAH genotype ( p > .05), and based on cannabis use ( p > .05). To address collinearity of AEA, OEA and PEA, we performed a principal components analysis, which identified a single component of FAAH substrates. Linear regressions found that FAAH genotype did not affect QST measures and that baseline 2-AG and FAAH substrate concentrations were not associated with QST measures, except pressure pain thresholds (PPT; p = 0.003), which were associated with AEA and OEA. Baseline eCB/NAE levels and FAAH genotype are not associated with the outcome measures of standard QST tests that rely on point estimates in healthy adult humans; nonetheless, circulating FAAH substrate levels were associated with PPT.
Open AccessThe Contribution of Baseline Circulating Endocannabinoids to Individual Differences in Human Pain Sensitivity: A Quantitative Sensory Testing Study
The endocannabinoid (eCB) system—comprising cannabinoid receptors, eCBs (anandamide— AEA, 2-arachidonoylglycerol—2-AG) and related N -acylethanolamines (NAEs; N- palmitoylethanolamide—PEA, and N- oleoylethanolamide—OEA), and metabolizing enzymes (e.g., fatty acid amide hydrolase; FAAH)—modulates nociceptive circuits in rodents. In humans, the FAAH C385A polymorphism is associated with reduced pain sensitivity, suggesting eCB tone influences individual pain differences, but this has yet to be tested. Here, we determined whether the eCB system is associated with somatosensory and pain sensitivity measured with quantitative sensory testing (QST) in 91 healthy participants (39 males, 52 females). We tested three hypotheses: (1) FAAH C385A polymorphism, cannabis use, and sex affect serum eCB/NAE concentrations; (2) FAAH C385A carriers show altered pain sensitivity versus non-carriers; and (3) baseline serum eCB/NAE concentrations are associated with QST measures. eCB/NAE concentrations were not statistically different based on sex ( p > .05), based on FAAH genotype ( p > .05), and based on cannabis use ( p > .05). To address collinearity of AEA, OEA and PEA, we performed a principal components analysis, which identified a single component of FAAH substrates. Linear regressions found that FAAH genotype did not affect QST measures and that baseline 2-AG and FAAH substrate concentrations were not associated with QST measures, except pressure pain thresholds (PPT; p = 0.003), which were associated with AEA and OEA. Baseline eCB/NAE levels and FAAH genotype are not associated with the outcome measures of standard QST tests that rely on point estimates in healthy adult humans; nonetheless, circulating FAAH substrate levels were associated with PPT.
- Open Access
- 27 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 457-470
Multifocal extramural venous invasion is a powerful predictor of adverse oncological outcomes in stages I– III colorectal cancer
Aims: This study aimed to determine the impact of venous invasion (VI) characteristics on oncological outcomes in colorectal cancer (CRC). Methods and Results: Resection specimens from 368 patients with TNM stages I–III CRC were assessed for VI including its presence/absence, location [intramural (IMVI) or extramural (EMVI)], number and size of the largest VI focus. VI and EMVI were identified in 55% and 32% of cases, respectively. EMVI, but not IMVI, was significantly associated with decreased 5‐year recurrence‐free survival (RFS) and disease‐specific survival (DSS) (hazard ratio [HR] 4.2, 95% confidence interval CI [2.6–6.9] and 3.7 [95% CI 1.9–6.9], p < 0.0001, respectively). Multifocal EMVI (mEMVI), defined as 2 or more EMVI foci, was identified in 67% of EMVI‐positive cases. In multivariable analysis, EMVI (HR 2.4 [95% CI 1.3–4.3], P = 0.003) and mEMVI (HR 2.4 [95% CI: 1.3–4.4], P = 0.02) were independently associated with RFS and demonstrated stronger associations than all other examined features, including T and N stage. These associations were maintained when the cohort was expanded to include 113 patients who received neoadjuvant therapy in addition to the original 368 patients who had not (‘expanded cohort’, n = 481). An increasing number of EMVI foci was significantly associated with decreased RFS and DSS ( P < 0.0001). Patients with >5 EMVI foci ( n = 31) had a particularly poor prognosis with 5‐year RFS and DSS of 29% and 56%, respectively. EMVI dimensions were not associated with oncological outcomes. Conclusions: Extramural location and multifocality are features of VI strongly associated with adverse oncological outcomes. If externally validated, incorporation of EMVI multifocality into future reporting protocols merits consideration.
- 27 August 2025
- Published by Wiley in Histopathology
- Vol. 88 (2) , 457-470
Open AccessMultifocal extramural venous invasion is a powerful predictor of adverse oncological outcomes in stages I– III colorectal cancer
Aims: This study aimed to determine the impact of venous invasion (VI) characteristics on oncological outcomes in colorectal cancer (CRC). Methods and Results: Resection specimens from 368 patients with TNM stages I–III CRC were assessed for VI including its presence/absence, location [intramural (IMVI) or extramural (EMVI)], number and size of the largest VI focus. VI and EMVI were identified in 55% and 32% of cases, respectively. EMVI, but not IMVI, was significantly associated with decreased 5‐year recurrence‐free survival (RFS) and disease‐specific survival (DSS) (hazard ratio [HR] 4.2, 95% confidence interval CI [2.6–6.9] and 3.7 [95% CI 1.9–6.9], p < 0.0001, respectively). Multifocal EMVI (mEMVI), defined as 2 or more EMVI foci, was identified in 67% of EMVI‐positive cases. In multivariable analysis, EMVI (HR 2.4 [95% CI 1.3–4.3], P = 0.003) and mEMVI (HR 2.4 [95% CI: 1.3–4.4], P = 0.02) were independently associated with RFS and demonstrated stronger associations than all other examined features, including T and N stage. These associations were maintained when the cohort was expanded to include 113 patients who received neoadjuvant therapy in addition to the original 368 patients who had not (‘expanded cohort’, n = 481). An increasing number of EMVI foci was significantly associated with decreased RFS and DSS ( P < 0.0001). Patients with >5 EMVI foci ( n = 31) had a particularly poor prognosis with 5‐year RFS and DSS of 29% and 56%, respectively. EMVI dimensions were not associated with oncological outcomes. Conclusions: Extramural location and multifocality are features of VI strongly associated with adverse oncological outcomes. If externally validated, incorporation of EMVI multifocality into future reporting protocols merits consideration.